What are the spectra of activity of commonly used antifungal agents and how do they differ?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Spectrum of Activity of Common Antifungal Agents

The major antifungal classes differ fundamentally in their spectrum: azoles and polyenes have broad activity against yeasts and molds, echinocandins are potent against most Candida species but only fungistatic against Aspergillus, and fluconazole specifically lacks any anti-mold activity.

Polyenes (Amphotericin B Formulations)

Amphotericin B products possess the broadest antifungal spectrum of all available agents 1:

  • Active against: Most Candida species (including C. krusei and C. glabrata), Aspergillus species, Cryptococcus, Mucorales (zygomycosis), and dimorphic fungi 1, 2
  • Dosing varies by indication: 0.5-1.0 mg/kg/day for invasive candidiasis, 1.0-1.5 mg/kg/day for invasive aspergillosis, and 3-10 mg/kg/day for invasive zygomycosis 2
  • Lipid formulations (L-AmB, ABLC, ABCD) have identical spectrum to amphotericin B deoxycholate but with significantly reduced nephrotoxicity, allowing higher dosing (3-5 mg/kg daily for candidiasis and aspergillosis, 4-6 mg/kg/day for cryptococcosis) 1, 2
  • Critical limitation: Lipid formulations may have reduced urinary penetration, making them theoretically less suitable for urinary tract candidiasis 1

Triazoles: Spectrum Varies Dramatically by Agent

Fluconazole (Narrow Spectrum)

Fluconazole completely lacks activity against invasive mold infections and is useful only for Candida prophylaxis 3:

  • Active against: Most Candida species, Cryptococcus 4, 2
  • Intrinsically resistant organisms: C. krusei (intrinsic resistance), C. glabrata (dose-dependent susceptibility with higher MICs) 4
  • No activity against: Aspergillus, Mucorales, or any mold infections 3
  • Standard dosing: 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) daily for invasive candidiasis 2

Voriconazole (Broad Spectrum, Mold-Active)

Voriconazole is FDA-approved for primary treatment of invasive aspergillosis and has activity against most Candida species 5:

  • Active against: All common Aspergillus species, most Candida species, Cryptococcus 5
  • Not recommended for: Fluconazole-resistant Candida species (except C. krusei where it has some activity), and specifically discouraged for most resistant Candida 4
  • No activity against: Mucorales (zygomycosis) 5
  • Dosing: 400 mg (6 mg/kg) every 12 hours for two doses on Day 1, then 200 mg (3-4 mg/kg) twice daily 2
  • Critical caveat: Wide pharmacokinetic variability due to CYP2C19 polymorphisms requires consideration of therapeutic drug monitoring 4

Itraconazole (Mold-Active, Limited Use)

Itraconazole has mold activity but is FDA-approved only for salvage therapy in aspergillosis 5:

  • Active against: Aspergillus species, most Candida species, dimorphic fungi 5
  • Dosing: 600 mg/day for 3 days, followed by 400 mg/day (tablet formulation) 2
  • Major limitation: Unpredictable bioavailability, particularly with oral suspension formulation 4

Posaconazole (Broad Spectrum, No Primary Candidiasis Indication)

Posaconazole demonstrates in vitro activity similar to voriconazole against Candida but lacks adequate clinical data for primary candidiasis therapy 4:

  • FDA-approved for: Prevention of invasive aspergillosis in high-risk neutropenic patients and HSCT recipients with GVHD 5, 6
  • Active against: Aspergillus species, Candida species, Mucorales 6
  • Dosing: 300 mg twice daily for 2 doses, then 300 mg daily (extended-release tablet or IV formulation provides predictable levels) 4

Isavuconazole (Emerging Agent)

Isavuconazole has excellent in vitro activity against Candida species but failed to meet noninferiority criteria versus echinocandins in invasive candidiasis trials 4:

  • Active against: Candida species, Aspergillus species, Mucorales 4
  • Current status: Not recommended as first-line for invasive candidiasis based on trial results 4

Echinocandins (Potent Anti-Candida, Fungistatic Against Molds)

Echinocandins have fungicidal activity against Candida species but are only fungistatic toward Aspergillus species 6:

Spectrum Characteristics

  • Excellent activity against: Most Candida species including C. glabrata and C. krusei (with low MICs) 4
  • Innately higher MICs: C. parapsilosis demonstrates higher MICs, raising concern for reduced clinical response 4
  • Emerging resistance: Recent case series describe treatment failures with resistant C. glabrata strains 4
  • Fungistatic only against: Aspergillus species (not fungicidal) 6
  • Limited or no activity against: Dimorphic fungi, Cryptococcus 6

Individual Agents (Caspofungin, Micafungin, Anidulafungin, Rezafungin)

All three traditional echinocandins have demonstrated efficacy in invasive candidiasis with pooled analyses suggesting survival advantage over other agents in nonneutropenic patients 4:

  • Dosing: Caspofungin 70 mg loading then 50 mg daily; Micafungin 100 mg daily; Anidulafungin 200 mg loading then 100 mg daily 2
  • Critical limitation: Do not achieve therapeutic concentrations in eye, CNS, or urine 4
  • Advantage: Minimal adverse effects and limited drug-drug interactions compared to azoles 4, 6

Flucytosine (Adjunctive Agent)

Flucytosine demonstrates broad activity against most Candida species except C. krusei 4:

  • Active against: Most Candida species, Cryptococcus 4
  • No activity against: C. krusei, molds 4
  • Dosing: 25 mg/kg four times daily for patients with normal renal function 2
  • Critical limitation: Available only as oral formulation in the United States with short half-life (2.4-4.8 hours) 4
  • Typical use: Combination therapy (particularly with amphotericin B for cryptococcal meningitis) rather than monotherapy 2

Key Clinical Decision Points

For Candida Infections

Echinocandins are preferred for most invasive candidiasis based on survival data, with fluconazole reserved for less critically ill patients or step-down therapy 4:

  • Echinocandins: Broad Candida coverage including resistant species, but avoid for CNS/eye/urinary infections 4
  • Fluconazole: Excellent for susceptible species with CNS/urinary penetration, but no C. krusei activity and variable C. glabrata susceptibility 4
  • Amphotericin B: Broadest spectrum when species unknown or for resistant organisms 1

For Mold Infections (Aspergillosis)

Voriconazole is the primary agent for invasive aspergillosis, with amphotericin B formulations as alternatives 5:

  • Voriconazole: FDA-approved primary therapy 5
  • Amphotericin B (especially lipid formulations): Alternative with broader spectrum including Mucorales 5
  • Echinocandins: Only fungistatic against Aspergillus; reserved for salvage or combination therapy 6
  • Never use fluconazole: Completely lacks anti-mold activity 3

For Mucorales (Zygomycosis)

Amphotericin B formulations are the only effective agents, requiring high doses (3-10 mg/kg/day) and mandatory surgical debridement 2:

  • Posaconazole and isavuconazole have activity but limited clinical data 6
  • No activity: Fluconazole, voriconazole, echinocandins 5

For Cryptococcosis

Amphotericin B plus flucytosine for induction, followed by fluconazole consolidation 2:

  • Induction: Amphotericin B deoxycholate plus flucytosine for 2 weeks, or L-AmB for 6-10 weeks 2
  • Consolidation/maintenance: Fluconazole 200-400 mg daily 2
  • Alternatives: Itraconazole, voriconazole (less data) 2

Common Pitfalls

Patients receiving fluconazole prophylaxis who develop breakthrough fungal infection are at risk for fluconazole-resistant Candida (C. krusei, C. glabrata) or invasive mold infections due to lack of anti-mold activity 3. In this scenario, empirical therapy must cover molds with voriconazole, amphotericin B, or an echinocandin 3.

Echinocandins cannot be used for CNS, ocular, or urinary tract fungal infections due to inadequate penetration 4. For these sites, choose fluconazole, voriconazole, flucytosine, or amphotericin B formulations 4.

Drug-drug interactions with azoles (particularly voriconazole, itraconazole, posaconazole) through CYP3A4 inhibition can cause toxicity with proteasome inhibitors, tyrosine kinase inhibitors, and vinca alkaloids 6. Consider echinocandin prophylaxis instead when these interactions are problematic 6.

References

Related Questions

What are effective strategies to memorize antifungal drug classes and their representative agents?
In a 79-year-old patient receiving enteral tube feeding who presents with diarrhea, which stool test should be ordered first?
In a 55‑year‑old man with a recent electrocardiogram showing sinus rhythm, a QS complex in V1, poor R‑wave progression in V2, left‑atrial enlargement, and a prolonged QT interval, what is the most likely diagnosis and appropriate treatment?
How do I convert an infusion rate of 60 cc per hour to drops per minute using a microdrip set?
A 68-year-old white male, 21 days post total hip arthroplasty, has itching at the clean, dry surgical site without drainage; what measures can be taken to resolve or minimize the itching?
In a 45-year-old woman with chronic alcohol use disorder who achieved return of spontaneous circulation after a pulseless electrical activity cardiac arrest and now shows inverted T waves on ECG, what is the most appropriate next step: 50 mEq sodium bicarbonate, 100 mg thiamine, 2 g magnesium sulfate, or 20 mEq potassium chloride?
An adult male on testosterone injections reports occasional rectal bleeding; how should this be evaluated and managed?
What is the appropriate treatment for hyponatremia, hypochloremia, and hypocalcemia (serum calcium 7.2 mg/dL)?
Why does an 84-year-old woman experience higher blood pressure upon standing?
What are the potential causes of unilateral lower extremity edema other than deep vein thrombosis?
What is the appropriate management for bilateral shin pruritus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.